亚洲色图国产,国内精品久久久久久久影视简单,激情四射五月天婷婷,中日韩欧美精彩视频,av高清免费,国产91电影在线观看,日本免费三片在线播放

關(guān)于我們
研發(fā)服務(wù)
服務(wù)平臺(tái)
客戶(hù)中心
新聞資訊
投資者關(guān)系
人力資源
EN
×
EN

  • 業(yè)務(wù)咨詢(xún)

    中國(guó)：

    Email: marketing@medicilon.com.cn

    業(yè)務(wù)咨詢(xún)專(zhuān)線(xiàn)：400-780-8018

    （僅限服務(wù)咨詢(xún)，其他事宜請(qǐng)撥打川沙總部電話(huà)）

    川沙總部電話(huà): +86 (21) 5859-1500

    海外：

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com
在線(xiàn)留言×
點(diǎn)擊切換
Customer Center
客戶(hù)中心
Jun 28,2023
ARD-2128是一種PROTAC AR降解劑，具有出色的血漿和微粒體穩(wěn)定性，本研究中體外穩(wěn)定性和PK研究通過(guò)美迪西進(jìn)行
ARD-2128 has excellent plasma and microsomal stability in all the five species (Human, Mouse, Rat, Dog, and Monkey). The in vitro stability and pharmacokinetic (PK) studies were performed by Medicilon.
查看更多
ARD-2128是一種PROTAC AR降解劑，具有出色的血漿和微粒體穩(wěn)定性，本研究中體外穩(wěn)定性和PK研究通過(guò)美迪西進(jìn)行
Jun 28,2023
設(shè)計(jì)合成一系列DHODH抑制劑作為潛在的類(lèi)風(fēng)濕性關(guān)節(jié)炎治療藥物，本研究中PK實(shí)驗(yàn)通過(guò)美迪西進(jìn)行
Human dihydroorotate dehydrogenase (DHODH) is a viable target for the development of therapeutics to treat cancer and immunological diseases. Herein, researchers designed and synthesized a series of acrylamide-based novel DHODH inhibitors as potential rheumatoid arthritis (RA) treatment agents.
查看更多
設(shè)計(jì)合成一系列DHODH抑制劑作為潛在的類(lèi)風(fēng)濕性關(guān)節(jié)炎治療藥物，本研究中PK實(shí)驗(yàn)通過(guò)美迪西進(jìn)行
Jun 28,2023
開(kāi)發(fā)并驗(yàn)證新的LC-MS/MS方法，用于定量人血漿中達(dá)拉非尼及其主要代謝物羥基達(dá)拉非尼 (OHD)。本研究中OHD(純度>99%)通過(guò)美迪西合成
OHD (purity >99 %) was synthesized by Medicilon. Medicilon synthetic chemistry team is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate drug discovery.
查看更多
開(kāi)發(fā)并驗(yàn)證新的LC-MS/MS方法，用于定量人血漿中達(dá)拉非尼及其主要代謝物羥基達(dá)拉非尼 (OHD)。本研究中OHD(純度>99%)通過(guò)美迪西合成
Jun 28,2023
放射療法用作肺癌的主要治療方法，本研究中建立抗電離輻射肺癌細(xì)胞系的放射治療通過(guò)美迪西進(jìn)行
Radiation therapy is used as the primary treatment for lung cancer. In this study, radiation therapy for establish ionizing radiation-resistant lung cancer cell lines (A549-IR/H1299-IR) was supported by Medicilon.
查看更多
放射療法用作肺癌的主要治療方法，本研究中建立抗電離輻射肺癌細(xì)胞系的放射治療通過(guò)美迪西進(jìn)行
Jun 28,2023
CAR-T療法主要針對(duì)白血病與惡性淋巴瘤，本研究中構(gòu)建沉默PD-1的shRNA載體質(zhì)粒，測(cè)序后質(zhì)粒的鑒定通過(guò)美迪西進(jìn)行
Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The shRNA vector plasmid that silences PD-1 and preparation of CAR is constructed. The plasmids sequenced were fully identified by Medicilon.
查看更多
CAR-T療法主要針對(duì)白血病與惡性淋巴瘤，本研究中構(gòu)建沉默PD-1的shRNA載體質(zhì)粒，測(cè)序后質(zhì)粒的鑒定通過(guò)美迪西進(jìn)行
Jun 28,2023
索拉非尼的無(wú)定形固體分散體用于開(kāi)發(fā)改良型口服生物利用度高的速釋片劑，本研究中PK實(shí)驗(yàn)通過(guò)美迪西進(jìn)行
The SOR ASD tablets exhibited approximately 50% higher relative bioavailability in dogs than the marketed SOR tablet product, Nexavar?. The pharmacokinetic (PK) study of SOR ASD tablets and Nexavar? tablets was performed by Medicilon.
查看更多
索拉非尼的無(wú)定形固體分散體用于開(kāi)發(fā)改良型口服生物利用度高的速釋片劑，本研究中PK實(shí)驗(yàn)通過(guò)美迪西進(jìn)行
Jun 28,2023
TAK-931是一種高特異性CDC7抑制劑，具有抗腫瘤功效，本研究中體內(nèi)藥效實(shí)驗(yàn)通過(guò)美迪西進(jìn)行
In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies were performed at Medicilon.
查看更多
TAK-931是一種高特異性CDC7抑制劑，具有抗腫瘤功效，本研究中體內(nèi)藥效實(shí)驗(yàn)通過(guò)美迪西進(jìn)行
Jun 28,2023
GS-5801是一種高效KDM5抑制劑，具有抗HBV活性，本研究中GS-5801通過(guò)美迪西合成
GS-5801, a potent inhibitor of KDM5, has antiviral activity against HBV in a primary human hepatocytes infection model, with the cellular permeability, oral bioavailability. GS-5801 was synthesized by Medicilon.
查看更多
GS-5801是一種高效KDM5抑制劑，具有抗HBV活性，本研究中GS-5801通過(guò)美迪西合成
Jun 28,2023
QF-036是一種高效的HIV-1抑制劑，具有良好的和藥代動(dòng)力學(xué)特性，PK研究通過(guò)美迪西進(jìn)行
The favourable viral inhibitory activity and pharmacokinetic properties provide critical support for QF-036 as a promising anti-HIV therapeutic candidate. The pharmacokinetic studies were performed by Medicilon.
查看更多
QF-036是一種高效的HIV-1抑制劑，具有良好的和藥代動(dòng)力學(xué)特性，PK研究通過(guò)美迪西進(jìn)行
Jun 28,2023
設(shè)計(jì)合成一種新型選擇性的口服有效蘇氨酸酪氨酸激酶 (TTK) 抑制劑，PK研究均通過(guò)美迪西進(jìn)行
TTK inhibition is an attractive wide-spectrum strategy for cancer therapy. Researchers designed and synthesized a series of pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable TTK inhibitors. All the pharmacokinetic studies were carried out by Medicilon.
查看更多
設(shè)計(jì)合成一種新型選擇性的口服有效蘇氨酸酪氨酸激酶 (TTK) 抑制劑，PK研究均通過(guò)美迪西進(jìn)行
×
搜索驗(yàn)證
點(diǎn)擊切換